Emerging growth opportunities in the next-generation immune checkpoint inhibitors market include the development of therapies targeting novel immune pathways employed to tackle cancer resistance ...

The medications most likely to cause thyroid eye disease are alemtuzumab, certain immune checkpoint inhibitors, amiodarone ...

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...

Prospective clinical trials needed to validate the findings ...

Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...

When immune checkpoint inhibitors are used in cancer treatment, in some cases it can lead to severe inflammation and damage to heart tissue. Histology images of mouse heart tissue illustrate the ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...